These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38846490)

  • 1. Ketogenic diet enhances the anti-cancer effects of PD-L1 blockade in renal cell carcinoma.
    Richard J; Beauvillain C; Benoit M; Barth M; Aubert C; Rolley C; Bellal S; Bourreau J; Ferragu M; Lebdai S; Chevrollier A; Henrion D; Procaccio V; Bigot P
    Front Endocrinol (Lausanne); 2024; 15():1344891. PubMed ID: 38846490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma.
    Hirayama Y; Gi M; Yamano S; Tachibana H; Okuno T; Tamada S; Nakatani T; Wanibuchi H
    Cancer Sci; 2016 Dec; 107(12):1736-1744. PubMed ID: 27712020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma.
    Harada M; Iida Y; Kotani H; Minami T; Komohara Y; Eto M; Yoshikawa K; Uemura H
    Cancer Immunol Immunother; 2022 Feb; 71(2):339-352. PubMed ID: 34160685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade.
    Ferrere G; Tidjani Alou M; Liu P; Goubet AG; Fidelle M; Kepp O; Durand S; Iebba V; Fluckiger A; Daillère R; Thelemaque C; Grajeda-Iglesias C; Alves Costa Silva C; Aprahamian F; Lefevre D; Zhao L; Ryffel B; Colomba E; Arnedos M; Drubay D; Rauber C; Raoult D; Asnicar F; Spector T; Segata N; Derosa L; Kroemer G; Zitvogel L
    JCI Insight; 2021 Jan; 6(2):. PubMed ID: 33320838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Tumor Growth and Sensitization to Sunitinib by RNA Interference Targeting Programmed Death-ligand 1 in Mouse Renal Cell Carcinoma RenCa Model.
    Hara T; Miyake H; Hinata N; Fujisawa M
    Anticancer Res; 2019 Sep; 39(9):4737-4742. PubMed ID: 31519573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards effective CAIX-targeted radionuclide and checkpoint inhibition combination therapy for advanced clear cell renal cell carcinoma.
    Kleinendorst SC; Oosterwijk E; Molkenboer-Kuenen J; Frielink C; Franssen GM; Boreel DF; Tamborino G; Gloudemans M; Hendrikx M; Kroon D; Hillen J; Bussink J; Muselaers S; Mulders P; Konijnenberg MW; Wheatcroft MP; Twumasi-Boateng K; Heskamp S
    Theranostics; 2024; 14(9):3693-3707. PubMed ID: 38948062
    [No Abstract]   [Full Text] [Related]  

  • 7. Traditional Chinese medicine Bu-Shen-Jian-Pi-Fang attenuates glycolysis and immune escape in clear cell renal cell carcinoma: results based on network pharmacology.
    Zheng J; Xu W; Liu W; Tang H; Lu J; Yu K; Song X; Li F; Wang Y; Wang R; Chen L; Zhang H; Qiu Y; Wei G; Zhou X; Yang J
    Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34002799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments.
    Fumarola C; La Monica S; Bonelli M; Zoppi S; Alfieri R; Galetti M; Gnetti L; Campanini N; Pozzi G; Cavazzoni A; Mazzaschi G; Silini EM; Buti S; Petronini PG
    Biochem Pharmacol; 2024 Aug; 226():116397. PubMed ID: 38944394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Th2-like response and antitumor effect of anti-interleukin-4 mAb in mice bearing renal cell carcinoma.
    Takeuchi T; Ueki T; Sasaki Y; Kajiwara T; Li B; Moriyama N; Kawabe K
    Cancer Immunol Immunother; 1997 Jan; 43(6):375-81. PubMed ID: 9067410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity.
    Tanegashima T; Togashi Y; Azuma K; Kawahara A; Ideguchi K; Sugiyama D; Kinoshita F; Akiba J; Kashiwagi E; Takeuchi A; Irie T; Tatsugami K; Hoshino T; Eto M; Nishikawa H
    Clin Cancer Res; 2019 Aug; 25(15):4808-4819. PubMed ID: 31076547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long non-coding RNA PCAT1 drives clear cell renal cell carcinoma by upregulating YAP via sponging miR-656 and miR-539.
    Wang R; Zheng B; Liu H; Wan X
    Cell Cycle; 2020 May; 19(10):1122-1131. PubMed ID: 32286142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralization of interleukin-2 retards the growth of mouse renal cancer.
    Fukuhara H; Matsumoto A; Kitamura T; Takeuchi T
    BJU Int; 2006 Jun; 97(6):1314-21. PubMed ID: 16686731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade.
    Dai X; Bu X; Gao Y; Guo J; Hu J; Jiang C; Zhang Z; Xu K; Duan J; He S; Zhang J; Wan L; Liu T; Zhou X; Hung MC; Freeman GJ; Wei W
    Mol Cell; 2021 Jun; 81(11):2317-2331.e6. PubMed ID: 33909988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of CD74 inhibits growth and invasion in clear cell renal cell carcinoma through HIF-1α pathway.
    Ji SQ; Su XL; Cheng WL; Zhang HJ; Zhao YQ; Han ZX
    Urol Oncol; 2014 Feb; 32(2):153-61. PubMed ID: 23273913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knockdown of HMGB2 inhibits proliferation and invasion of renal tumor cells via the p-38MAPK pathway.
    He ZH; Guo F; Hu XX; Luo ZY; Yi JW
    Eur Rev Med Pharmacol Sci; 2020 May; 24(9):4729-4737. PubMed ID: 32432736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD1/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives.
    Zhu Z; Jin Y; Zhou J; Chen F; Chen M; Gao Z; Hu L; Xuan J; Li X; Song Z; Guo X
    Mol Cancer; 2024 Jul; 23(1):146. PubMed ID: 39014460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the extracellular matrix.
    Inamoto T; Yamochi T; Ohnuma K; Iwata S; Kina S; Inamoto S; Tachibana M; Katsuoka Y; Dang NH; Morimoto C
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3470-7. PubMed ID: 16740772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of glycolysis enhances the efficacy of immunotherapy via PDK-mediated upregulation of PD-L1.
    Zhang R; Mao G; Tang Y; Li C; Gao Y; Nie W; Song T; Liu S; Zhang P; Tao K; Li W
    Cancer Immunol Immunother; 2024 Jun; 73(8):151. PubMed ID: 38832951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TFEB Mediates Immune Evasion and Resistance to mTOR Inhibition of Renal Cell Carcinoma via Induction of PD-L1.
    Zhang C; Duan Y; Xia M; Dong Y; Chen Y; Zheng L; Chai S; Zhang Q; Wei Z; Liu N; Wang J; Sun C; Tang Z; Cheng X; Wu J; Wang G; Zheng F; Laurence A; Li B; Yang XP
    Clin Cancer Res; 2019 Nov; 25(22):6827-6838. PubMed ID: 31383732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of galectin-3 augments the antitumor efficacy of PD-L1 blockade in non-small-cell lung cancer.
    Zhang H; Liu P; Zhang Y; Han L; Hu Z; Cai Z; Cai J
    FEBS Open Bio; 2021 Mar; 11(3):911-920. PubMed ID: 33455075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.